WASHINGTON DC (July 1, 2021) – On the occasion of the one-year anniversary of the U.S.-Mexico-Canada Agreement coming into force, the Association for Accessible Medicines (AAM) releases the following statement:
One year ago today, the U.S.-Mexico-Canada Agreement set the standard for a modern trade agreement. By balancing support for pharmaceutical innovation with generic and biosimilar competition, USMCA is a win for companies, health systems, patients and taxpayers, said AAM President and CEO Dan Leonard.
The broad bipartisan support this agreement received in Congress demonstrates the importance of access to medicines as a key component of U.S. trade policy. The Association of Accessible Medicines stands with the Biden Administration, Congress and our trading partners in working to ensure that all future trade agreements reflect this critical balance.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.